Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis
- PMID: 26712637
- DOI: 10.1111/ijd.12839
Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis
Abstract
Background: Systemic sclerosis (SSc) is the most severe connective tissue disorder. Recent studies have demonstrated that genetic factors may play a role in the development of SSc. The aim of this study was to investigate the association of signal transducer and activator of transcription 4 (STAT4) rs7574865 and interferon regulatory factor 5 (IRF5) rs2004640 polymorphisms with risk of SSc.
Methods: Case-control studies were obtained from the electronic database of PubMed, Medline, Embase, and CNKI (China National Knowledge Infrastructure) up to December 2013. The association between STAT4 and IRF5 polymorphisms and SSc susceptibility was assessed by pooled odds ratios (ORs) and 95% confidence intervals (CI).
Results: Six related studies, including 4746 SSc cases and 7399 healthy controls, were pooled in this meta-analysis. For STAT4 polymorphism, we observed a statistically significant positive association between risk factor T allele carriers and SSc susceptibility (OR = 1.37, 95% CI = 1.27-1.48, P < 0.00001) in the overall population. The presence of limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) scleroderma also showed a significant association with each of the genetic models (P < 0.00001). For IRF5 polymorphism, the T allele was shown to be strongly associated with increased SSc risk (OR = 1.27, 95% CI = 1.17-1.39, P < 0.00001). No significant heterogeneity between studies was found.
Conclusions: The results demonstrated that STAT4 rs7574865 and IRF5 rs2004640G/T substitution are associated with a susceptibility to SSc, and they may serve as the SSc genetic susceptibility factor. These data confirmed that genetic polymorphisms may play a role in the development of SSc and have provided new insight into the pathogenesis of SSc.
© 2015 The International Society of Dermatology.
Similar articles
-
STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis.Arthritis Rheum. 2009 Aug;60(8):2472-9. doi: 10.1002/art.24688. Arthritis Rheum. 2009. PMID: 19644887
-
Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.Clin Rheumatol. 2020 Apr;39(4):1173-1179. doi: 10.1007/s10067-019-04922-6. Epub 2020 Jan 8. Clin Rheumatol. 2020. PMID: 31916109 Free PMC article.
-
BANK1 is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects with IRF5 and STAT4.Arthritis Rheum. 2009 Nov;60(11):3447-54. doi: 10.1002/art.24885. Arthritis Rheum. 2009. PMID: 19877059
-
The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms.Rheumatol Int. 2017 Aug;37(8):1303-1310. doi: 10.1007/s00296-017-3722-5. Epub 2017 Apr 22. Rheumatol Int. 2017. PMID: 28434122 Review.
-
Unfolding the pathogenesis of scleroderma through genomics and epigenomics.J Autoimmun. 2017 Sep;83:73-94. doi: 10.1016/j.jaut.2017.05.004. Epub 2017 May 16. J Autoimmun. 2017. PMID: 28526340 Free PMC article. Review.
Cited by
-
Updates on genetics in systemic sclerosis.Inflamm Regen. 2021 Jun 15;41(1):17. doi: 10.1186/s41232-021-00167-6. Inflamm Regen. 2021. PMID: 34130729 Free PMC article. Review.
-
Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.Open Access Rheumatol. 2022 Sep 15;14:171-186. doi: 10.2147/OARRR.S285409. eCollection 2022. Open Access Rheumatol. 2022. PMID: 36133926 Free PMC article. Review.
-
Genetics of systemic sclerosis.J Scleroderma Relat Disord. 2020 Oct;5(3):192-201. doi: 10.1177/2397198320913695. Epub 2020 Apr 19. J Scleroderma Relat Disord. 2020. PMID: 35382527 Free PMC article. Review.
-
The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.Front Immunol. 2022 May 24;13:900638. doi: 10.3389/fimmu.2022.900638. eCollection 2022. Front Immunol. 2022. PMID: 35686127 Free PMC article. Review.
-
Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway.Front Pharmacol. 2021 Sep 3;12:716672. doi: 10.3389/fphar.2021.716672. eCollection 2021. Front Pharmacol. 2021. PMID: 34539403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous